Outcomes of non-small cell lung cancer patients with non-V600E mutations: a series of case reports and literature review.
Fiche publication
Date publication
mars 2024
Journal
Frontiers in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr SCHOTT Roland
Tous les auteurs :
Lazar R, Fischbach C, Schott R, Somme L
Lien Pubmed
Résumé
Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting for approximately 85% of cases of lung cancer. The standard first-line therapy for patients without oncogenic driver metastatic NSCLC is anti PD-L1 immune checkpoint inhibition (ICI) with platinum-based chemotherapy. Approximately 4% of NSCLC patients harbor mutations; the V600E mutation is the most common. Non-V600 mutations is an heterogeneous population and account for approximately 50% of -mutated NSCLC. mutations are classified into 3 functional classes based on their kinase activity and their signaling mechanism. The European Medicines Agency and the United States Food and Drug Administration have approved dabrafenib, an anti-BRAF tyrosine kinase inhibitor (TKI), in combination with trametinib, an anti-MEK TKI, for the treatment of patients with V600E-mutated metastatic NSCLC. The use of targeted therapies in NSCLC with non-V600E mutations remains controversial. There is a lack of guidelines regarding therapeutic options in non-V600E -mutated NSCLC. Herein, we presented 3 cases of NSCLC with non-V600E mutations and reviewed the current state of therapies for this particular population of lung cancer.
Mots clés
BRAF non-V600E mutations, NSCLC, PD-L1, immunotherapy, targeted therapy
Référence
Front Oncol. 2024 03 27;14:1307882